Ruxolitinib Topical Cream [Opzelura]
RxNorm 2570756

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2570756 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ruxolitinib Topical Cream [Opzelura].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Ruxolitinib Topical Cream [Opzelura]
AUI:12686543
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Ruxolitinib Topical Cream [Opzelura]
(Atom ID: 12686543)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ruxolitinib Topical Cream [Opzelura]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2570756
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12686543
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
2570756
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Ruxolitinib Topical


Topical ruxolitinib is used to treat the symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in patients who cannot use other medications for their condition or whose eczema has not responded to another medication. Ruxolitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.
[Learn More]


* Please review the disclaimer below.